Table 2.
Proportion of patients with chronic kidney disease receiving apixaban who experienced bleeding events
| Population | 5 mg BID | 2.5 mg BID | P valuea | 10 mg BID |
|---|---|---|---|---|
| Overall | n = 22 | n = 73 | n = 3 | |
| Composite | 10 (46%) | 49 (67%) | 0.08 | 0 |
| Major | 2 (9%) | 9 (12%) | 1.00 | 0 |
| CRNMB | 5 (23%) | 17 (23%) | 1.00 | 0 |
| Minor | 8 (36%) | 40 (55%) | 0.07 | 0 |
| SCr >2.5 mg/dL or CrCl <25 mL/min | n = 8 | n = 33 | n = 0 | |
| Composite | 4 (50%) | 22 (67%) | 0.43 | – |
| Major | 0 | 5 (15%) | 0.56 | – |
| CRNMB | 1 (13%) | 7 (21%) | 1.00 | – |
| Minor | 3 (38%) | 16 (49%) | 0.70 | – |
| Hemodialysis | n = 10 | n = 35 | n = 1 | |
| Composite | 4 (40%) | 24 (69%) | 0.14 | 0 |
| Major | 1 (10%) | 4 (11%) | 1.00 | 0 |
| CRNMB | 3 (30%) | 8 (23%) | 0.69 | 0 |
| Minor | 4 (40%) | 22 (63%) | 0.28 | 0 |
a
For comparison between 5.0 and 2.5 mg BID doses.
BID indicates twice daily; CRNMB, clinically relevant nonmajor bleeding.